Angiogenesis in esophageal and gastric cancer: A paradigm shift in treatment

Expert Opinion on Biological Therapy

Volumn 14, Issue 9, 2014, Pages 1319-1332

  Barzi, Afsaneh ^a   Thara, Eddie ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Angiogenesis; Metastatic esophageal and gastric cancer; Ramucirumab; Target therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; ESOPHAGEAL NEOPLASMS; HUMAN; IMMUNOLOGY; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; STOMACH NEOPLASMS; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ESOPHAGEAL NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84905858700     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.921677     Document Type: Review

References (79)

1. Patan S. Vasculogenesis and angiogenesis. Cancer Treat Res 2004;117:3-32
2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-18
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
7. Barzi A, Lenz HJ. Angiogenesis-related agents in esophageal cancer. Expert Opin Biol Ther 2012;12:1335-45
8. Jemal A, Bray F, Center MM, et al. Global cancer statistics. American Cancer Society. A Cancer J Clin 2011;61:69-90
9. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
10. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
11. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
12. Society AC. Cancer facts and figures 2013. American Cancer Society; Atlanta: 2013
13. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53
14. Pandeya N, Williams G, Green AC, et al. Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus. Gastroenterology 2009;136:1215-24.e1-2
15. Chen ZM, Xu Z, Collins R, et al. Early health effects of the emerging tobacco epidemic in China. A 16-year prospective study. JAMA 1997;278:1500-4
16. Ribeiro U, Posner MC, Safatle-Ribeiro AV, et al. Risk factors for squamous cell carcinoma of the oesophagus. Br J Surg 1996;83:1174-85
17. Liyanage SS, Rahman B, Ridda I, et al. The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: A meta-Analysis. PLoS One 2013;8:e69238
18. Botterweck AA, Schouten LJ, Volovics A, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;29:645-54
19. Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: Scientific review. JAMA 2002;287:1972-81
20. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988;48:3554-60
21. Tricker AR. N-nitroso compounds and man: Sources of exposure, endogenous formation and occurrence in body fluids. Eur J Cancer Prev 1997;6:226-68
22. La Vecchia C, Negri E, Decarli A, et al. A case-control study of diet and gastric cancer in northern Italy. Int J Cancer 1987;40:484-9
23. Ladeiras-Lopes R, Pereira AK, Nogueira A, et al. Smoking and gastric cancer: Systematic review and meta-Analysis of cohort studies. Cancer Causes Control 2008;19:689-701
24. Figueiredo C, Machado JC, Pharoah P, et al. Helicobacter pylori and interleukin 1 genotyping: An opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002;94:1680-7
25. Van Cutsem E, Dicato M, Geva R, et al. The diagnosis and management of gastric cancer: Expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol 2011;22(Suppl 5):v1-9
26. Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): An open-label, phase 3 randomised controlled trial. Lancet Oncol 2014;15:78-86
27. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-6
28. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27
29. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin Cancer Res 2006;12:5018-22
30. Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-71
31. Menakuru SR, Brown NJ, Staton CA, et al. Angiogenesis in pre-malignant conditions. Br J Cancer 2008;99:1961-6
32. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5
33. Hariawala MD, Horowitz JR, Esakof D, et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 1996;63:77-82
34. Kim SE, Shim KN, Jung SA, et al. The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut Liver 2009;3:88-94
35. Lieto E, Ferraraccio F, Orditura M, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008;15:69-79
36. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-63
37. Song ZJ, Gong P, Wu YE. Relationship between the expression of iNOS,VEGF, tumor angiogenesis and gastric cancer. World J Gastroenterol 2002;8:591-5
38. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7
39. Jain RK. Normalization of tumor vasculature: An emerging concept in anti-Angiogenic therapy. Science 2005;307:58-62
40. Pries AR, Hopfner M, le Noble F, et al. The shunt problem: Control of functional shunting in normal and tumour vasculature. Nat Rev Cancer 2010;10:587-93
41. Demetri GD, Van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329-38
42. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13
43. Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2011;29:1449-58
44. Schmitt JM, Sommers SR, Fisher W, et al. Sunitinib plus paclitaxel in patients with advanced esophageal cancer: A phase II study from the Hoosier Oncology Group. J Thorac Oncol 2012;7:760-3
45. Yi JH, Lee J, Park SH, et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 2012;106:1469-74
46. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-18
47. Brose MS, Nutting C, Jarzab B, et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. ASCO Annual Meeting. J Clin Oncol 2013;31(Suppl):abstract 4
48. Sun W, Powell M, O'Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010;28:2947-51
49. Gallego R, Martin-Richard M, Pericay C, et al. Phase II study of oxaliplatin and sorafenib in advanced gastric cancer after failure of cisplatin-fluoropyrimidine-based (PF) treatment. 2012 ASCO Annual Meeting. J Clin Oncol 2012;30(Suppl):abstract 4079
50. Ku GY, Janjigian YY, Shah MA, et al. Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and prolonged stable disease observed in adenocarcinoma. 2013 Gastrointestinal Cancers Symposium. J Clin Oncol 2012;30(Suppl 34):abstract 91
51. Grothey A, Galanis E. Targeting angiogenesis: Progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-18
52. Ranieri G, Patruno R, Ruggieri E, et al. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: From the biology to the clinic. Curr Med Chem 2006;13:1845-57
53. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-6
54. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-76
55. Shah MA, Van Cutsem E, Kang Y-K, et al. Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer. 2012 Gastrointestinal Cancers Symposium. J Clin Oncol 2012;30(Suppl 4):abstract 5
56. Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: An update on ramucirumab. Expert Opin Biol Ther 2013;13:1187-96
57. Garcia-Carbonero R, Rivera F, Maurel J, et al. A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784. 2012 Gastrointestinal Cancers Symposium. J Clin Oncol 2012;30(Suppl 4):abstract 533
58. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-9
59. Wilke H, Van Cutsem E, Oh SC, et al. RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum-And fluoropyrimidinecontaining combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE), 2014 Gastrointestinal Cancers Symposium. J Clin Oncol 2014;32(Suppl 3):abstract LBA7
60. Chu QS. Aflibercept (AVE0005): An alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2009;9:263-71
61. Pan B, Lentzsch S. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol Ther 2012;136:56-68
62. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-82
63. Barton WA, Dalton AC, Seegar TC, et al. Tie2 and Eph receptor tyrosine kinase activation and signaling. Cold Spring Harb Perspect Biol 2014
64. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 2011;378:1931-9
65. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97
66. Barzi A, Stern MC, Zhang J, et al. Gastric cancer (GC) in California Cancer Registry (CCR): One disease, many faces. 2014 Gastrointestinal Cancers Symposium. J Clin Oncol 2014;32(Suppl 3):abstract 30
67. Wakatsuki T, Zhang W, Yang D, et al. Ethnic gene profile of genes involved in angiogenesis to predict regional bevacizumab efficacy difference in gastric cancer. 2012 ASCO Annual Meeting. J Clin Oncol 2012;30(Suppl):abstract 4026
68. Chow LQ, Eckhardt SG. Sunitinib: From rational design to clinical efficacy. J Clin Oncol 2007;25:884-96
69. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-34
70. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet 2013;381:303-12
71. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129:245-55
72. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8
73. El-Rayes BF, Zalupski M, Bekai-Saab T, et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010;21:1999-2004
74. Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011;29:868-74
75. Shen L, Li J, Xu J-M, et al. Efficacy and tolerability of bevacizumab (BEV) plus capecitabine and cisplatin (XP) in Chinese patients (pts) with locally advanced or metastatic gastric/gastroesophageal junction cancer (AGC): Results from the AVATAR study. 2012 Gastrointestinal Cancers Symposium. J Clin Oncol 2012;30(Suppl 4):abstract 73
76. Enzinger PC, Kwak EL, Szymonifka J, et al. Multicenter randomized phase II trial of cisplatin, irinotecan plus bevacizumab (PCA) versus docetaxel, cisplatin, irinotecan plus bevacizumab (TPCA) in patients (pts) with metastatic esophagogastric cancer (MEGCA). 2012 ASCO Annual Meeting. Chicago, Illinois. J Clin Oncol 2012;30(Suppl):abstract 4027
77. Purim O, Kundel Y, Gonik US, et al. Weekly docetaxel and cisplatin with capecitabine and bevacizumab (AVDCX) in patients with advanced esophagogastric cancer: Results of a phase Ib/II study, 2013 ASCO Annual Meeting. Chicago, Illinois. J Clin Oncol 2013;31(Suppl):abstract e15078
78. Woell E, Keil F, Thaler J, et al. Oxaliplatin, irinotecan, bevacizumab followed by docetaxel, bevacizumab in inoperable gastric cancer: Final efficacy results of a multicenter phase II trial (AGMT Gastric-3) of the arbeitsgemeinschaft Medikamentose tumortherapie (AGMT), ASCO Annual Meeting. Chicago, Illinois. J Clin Oncol 2013;31(Suppl):abstract e15041
79. Kunz PL, Nandoskar P, Koontz MZ, et al. A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma. Gastrointestinal Cancers Symposium. J Clin Oncol 2014;32(Suppl 3):abstract 115